Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study

Targeting L858R/T790M and L858R/T790M/C797S mutant EGFR is a critical challenge in developing EGFR tyrosine kinase inhibitors to overcome drug resistance in non-small cell lung cancer (NSCLC). The discovery of next-generation EGFR tyrosine kinase inhibitors (TKIs) is therefore necessary. To this end...

Descripción completa

Detalles Bibliográficos
Autores principales: Todsaporn, Duangjai, Zubenko, Alexander, Kartsev, Victor, Aiebchun, Thitinan, Mahalapbutr, Panupong, Petrou, Anthi, Geronikaki, Athina, Divaeva, Liudmila, Chekrisheva, Victoria, Yildiz, Ilkay, Choowongkomon, Kiattawee, Rungrotmongkol, Thanyada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10096398/
https://www.ncbi.nlm.nih.gov/pubmed/37049777
http://dx.doi.org/10.3390/molecules28073014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10096398/
https://www.ncbi.nlm.nih.gov/pubmed/37049777
http://dx.doi.org/10.3390/molecules28073014

Ejemplares similares